Medicine Pharmacy Nutrition

Healthcare News and Reviews

  • Welcome
  • News

biopharma nl

Flagship Pioneering’s Senda Bio secures $123M for new ‘programmable medicines’

August 16, 2022 AutoBot 0

Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to […]

Don’t wait until it’s too late: Now’s the time to leverage cybersecurity standards for the production environment

August 16, 2022 AutoBot 0

Today’s factory floors include production equipment that’s linked directly into those IT systems that are so often the victims of a cyberattack. This “operational technology” […]

Merck picks circular path to RNA and commits $250M to biotech startup Orna

August 16, 2022 AutoBot 0

Merck aims to bolster its genetic medicines pipeline through a new research alliance with Orna Therapeutics, a startup whose technology forms RNA into a circle […]

Gilead claims breast cancer trial win but offers few details; drug application is filed with FDA

August 15, 2022 AutoBot 0

Gilead Sciences said it has statistically significant and clinically meaningful data from a pivotal test of its cancer drug, Trodelvy, in the most common type […]

No Image

Current advancements in wet AMD are not enough

August 15, 2022 AutoBot 0

AMD in particular impacts as many as 11 million Americans. About 15% of those affected have neovascular or wet AMD. It’s a devastating disease that […]

No Image

AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer

August 14, 2022 AutoBot 0

On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell […]

No Image

Novartis warns of two patients deaths after dosing with gene therapy Zolgensma

August 12, 2022 AutoBot 0

The two deaths reported following treatment with Novartis’s Zolgensma mark the first fatal cases of acute liver failure associated with the gene therapy. Liver complications […]

No Image

340B entities face increased challenges in a shifting regulatory and enforcement landscape

August 11, 2022 AutoBot 0

Concerns about who qualifies under the 340B Program, how drugs can be dispensed to patients, and how much entities will be reimbursed may significantly impact […]

No Image

After RNA therapy falls short in the eye, ProQR Therapeutics pivots to liver, CNS

August 11, 2022 AutoBot 0

RNA therapies developer ProQR Therapeutics is eying a future without ophthalmology. After receiving European Medicines Agency feedback for its lead program for a rare eye […]

No Image

BMS reports data that could give its cell therapy an edge over rival J&J product

August 10, 2022 AutoBot 0

Bristol Myers Squibb has data showing that its multiple myeloma treatment Abecma beat the standard of care, preliminary Phase 3 results that could support moving […]

No Image

Aduhelm’s loss is a win for value-based drug pricing

August 10, 2022 AutoBot 0

Value-based pricing could have shown us with more certainty the real level of effectiveness of Aduhelm. Maybe it is worth paying something for; and value-based […]

No Image

Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs

August 9, 2022 AutoBot 0

Merck is paying $25 million to kick off a research partnership with Cerevance, a startup that analyzes donor brain tissue to find novel targets for […]

No Image

GSK pays $100M to partner on a cancer drug with new twist on immunotherapy

August 9, 2022 AutoBot 0

GSK is partnering with Mersana Therapeutics on the development of an antibody-drug conjugate that is approaching Phase 1 testing. Unlike other ADCs that deliver a […]

No Image

FDA approval of AstraZeneca drug is first for a new group of breast cancer patients

August 5, 2022 AutoBot 0

Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein […]

No Image

Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy

August 5, 2022 AutoBot 0

Amgen’s drug portfolio boasts several biologic drugs that are blockbuster sellers. In acquiring ChemoCentryx for $3.7 billion, the pharmaceutical giant gains a company entirely focused […]

No Image

Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal

August 4, 2022 AutoBot 0

Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was […]

No Image

The power of digital ecosystems to improve pharma supply chain operations [Sponsored]

August 3, 2022 AutoBot 0

A panel discussion from a recent Microsoft summit offered insights on how tech companies are closely collaborating with the pharma industry as they seek to […]

No Image

Ipsen’s latest R&D alliance brings novel T cell-activating drugs for cancer

August 2, 2022 AutoBot 0

Ipsen has been an active dealmaker lately, and it just struck another one that takes the pharmaceutical company into a new area of drug research. […]

No Image

Aiming to bring drug combos into earlier lines of cancer therapy, IDRx lands $122M

August 2, 2022 AutoBot 0

Taking inspiration from the success of drug cocktails that halt viral infections, startup IDRx aims to develop cancer drug combinations that stop tumor escape. The […]

No Image

Digital transformation: Reimagining clinical trial management [Sponsored]

August 2, 2022 AutoBot 0

Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there’s a need for a hybrid approach […]

No Image

FDA hits pause on Beam Therapeutics’ off-the-shelf cell therapy for blood cancers

August 1, 2022 AutoBot 0

Beam Therapeutics’ application to begin human testing of a cell therapy made with base-editing technology is now under an FDA clinical hold. In other clinical […]

No Image

Novartis, UC Berkeley-spawned startup snags $65M to keep key proteins out of the cell’s trash can

July 31, 2022 AutoBot 0

Vicinitas Therapeutics is developing small molecule drugs that stabilize key proteins, preventing them from going to a cell’s built-in disposal system. The startup, which stems […]

No Image

U.S. government places $1.74B order for Moderna’s new Covid-19 vaccine boosters

July 29, 2022 AutoBot 0

The U.S. government has signed a supply agreement securing 66 million doses of Moderna’s Covid-19 vaccine booster shots, which are designed to address the omicron […]

No Image

Health equity should start at birth

July 24, 2022 AutoBot 0

Pregnant women and others able to give birth are severely underrepresented in clinical research globally. But real-world data – when relevant, reliable, and fit for […]

No Image

Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?

July 22, 2022 AutoBot 0

Kidney disease patients need access to innovative therapies to expand treatment choices and improve quality of life. The FDA should closely examine whether it is […]

No Image

DOJ charges dozens for $1.2B in telemedicine fraud scheme

July 21, 2022 AutoBot 0

The charges involve some of the first cases in the country involving fraudulent cardiovascular genetic testing, a “burgeoning scheme,” according to a news release from […]

No Image

Elevating patient care from the home

July 20, 2022 AutoBot 0

By adding adherence and connectivity capabilities to home-based solutions, clinicians can maintain open lines of communication with patients, helping patients better care for themselves from […]

No Image

Lowering insulin prices isn’t the (only) answer to helping patients with diabetes

July 18, 2022 AutoBot 0

It is time to shift the conversation, incentives, and policy solutions to help people improve their health and get off of medications—not just make them […]

No Image

Reimagining healthcare in a quantum era

July 17, 2022 AutoBot 0

With promises of more efficient and reliable diagnoses, future breakthroughs in personalized medicine and targeted therapeutics, and an expedited R&D lifecycle, industry leaders must be […]

No Image

Novartis turns to algorithms developer Anumana to apply AI to cardio conditions

July 15, 2022 AutoBot 0

Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect […]

No Image

FDA delay means BeiGene, Novartis must wait longer for cancer drug decision

July 14, 2022 AutoBot 0

The FDA has deferred a regulatory decision on an esophageal cancer drug from partners BeiGene and Novartis, citing the need to complete inspections of the […]

No Image

Monoclonal antibodies are the way out of the Covid-19 pandemic

July 13, 2022 AutoBot 0

Whether they are acting as a therapeutic or preventive treatment, monoclonal antibodies can allow us to help contain the virus, where we might see the […]

No Image

New York AG: Teva USA’s parent company shouldn’t be allowed to escape opioid liability

July 13, 2022 AutoBot 0

Without the parent company, there’s concern Teva won’t be able to pay billions in reward to NY state.

No Image

Why stigma continues to exacerbate the United States’ drug epidemic

July 12, 2022 AutoBot 0

Since we know the fundamental causes of the opioid epidemic, why are we still here? It all centers around stigma.

No Image

Neuro startups form latest group of grads from PharmStars digital health accelerator

July 12, 2022 AutoBot 0

PharmStars, a digital health accelerator, graduated its latest cohort of startups, each of them developing a solution addressing some aspect of neurological disease. The accelerator […]

No Image

Areteia gets $350M to turn failed ALS drug into a therapy for severe asthma

July 12, 2022 Auto Bot 0

New company Areteia Therapeutics launched with up to $350 million in financing and an asthma drug candidate from Knopp Biosciences. That drug, dexpramipexole, previously failed […]

No Image

Roche pays $55M for late-stage drug for rare kidney disease with no approved treatment

July 11, 2022 Auto Bot 0

An Ionis Pharmaceuticals drug has positive Phase 2 results in immunoglobulin A nephropathy, leading Roche to exercise its option to license the rights to the […]

No Image

Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout

July 11, 2022 Auto Bot 0

Vertex Pharmaceuticals already has a cell therapy candidate for type 1 diabetes but the company says acquiring rival ViaCyte will provide it with complementary assets […]

No Image

Pfizer, BioNTech Covid-19 vaccine gets full FDA approval for adolescents

July 10, 2022 Auto Bot 0

The FDA has granted the Pfizer and BioNTech Covid-19 full approval for use in adolescents. In other Covid-19 news, pharmacists were granted additional prescribing powers […]

No Image

AbbVie & Alector drop Alzheimer’s med from alliance, shifting focus to a 2nd drug

July 8, 2022 Auto Bot 0

AbbVie paid Alector $205 million up front five years ago to begin an R&D partnership on two drugs intended to bring an immunotherapy approach to […]

No Image

FDA says pharmacists can prescribe Covid treatment

July 8, 2022 Auto Bot 0

The AMA believes physicians should still be the main prescribers, while advocates for provider status for pharmacists say it’s a win for health equity and […]

No Image

Amgen joins Kernal Bio’s $25M financing as the startup brings mRNA 2.0 to cancer

July 7, 2022 Auto Bot 0

Kernal Biologics has technology that enables the delivery of messenger RNA therapies to a wider range of destinations in the body. The Series A financing […]

No Image

W. Va. judge sides with drug distributors in bellwether opioid trial

July 7, 2022 Auto Bot 0

From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 to 213.9 per 100,000. Judge finds no evidence of causation.

No Image

After initial failure, Intercept Pharma feels new data can get NASH drug approval

July 7, 2022 Auto Bot 0

Two years after the stinging FDA rejection of its drug for the fatty liver disease NASH, Intercept Pharmaceuticals has more safety and efficacy data from […]

No Image

How Pfizer won the pandemic, reaping outsize profit and influence

July 6, 2022 Auto Bot 0

Because the virus keeps mutating and will be around for a long time, the market for Pfizer’s products won’t go away. In wealthier countries, the […]

No Image

With new gene therapy data in hand, Sarepta talks with FDA about approval pathways

July 6, 2022 Auto Bot 0

Sarepta Therapeutics has more clinical data showing the safety and efficacy of its experimental gene therapy for Duchenne muscular dystrophy. A pivotal Phase 3 test […]

No Image

How the agile in pharma trend is transforming drug development [Sponsored]

July 6, 2022 Auto Bot 0

Emergn Principal Consultant Mario Moreira shared insights on how pharma companies can use the principles of Value, Flow and Quality to shorten drug development timelines […]

No Image

CureVac sues BioNTech, claiming Covid-19 vaccine infringes key mRNA patents

July 5, 2022 Auto Bot 0

Messenger RNA vaccine biotech CureVac is suing BioNTech, alleging that its rival’s Covid-19 vaccine infringes on intellectual property built on more than two decades of […]

No Image

Novartis pays $100M to get Mallinckrodt’s ticket for a speedier FDA drug review

July 1, 2022 Auto Bot 0

Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals. The $100 million price tag is in the neighborhood of the going rate for […]

No Image

As M&A costs rise, new Accenture report offers alternative strategies

July 1, 2022 Auto Bot 0

Rising deal premiums and shrinking profit margins are threatening the sustainability of the traditional approach to mergers and acqusitions, according to a report by Accenture. […]

No Image

Liver injury leads FDA to pause Sanofi’s tests of MS drug acquired in $3.7B deal

June 30, 2022 Auto Bot 0

The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. While U.S. […]

No Image

Feds commit $3.2B to lock in Covid-19 vax supply ahead of fall vaccination campaign

June 30, 2022 Auto Bot 0

New Covid-19 vaccine booster shots are coming and they’ll likely include protection against the omicron variant. The U.S. government agreed to a purchasing contract covering […]

No Image

Two for two: Sanofi snares twin European nods for enzyme replacement therapies

June 28, 2022 Auto Bot 0

Sanofi won European Commission approval for two therapies that treat rare enzyme deficiencies. Xenpoyzme is the first treatment for acid sphingomyelinase deficiency (ASMD) while Nexviadyme […]

No Image

Ipsen’s $247M Epizyme acquisition brings approved cancer drug & more in pipeline

June 27, 2022 Auto Bot 0

Ipsen is paying $247 million to acquire Epizyme, a cancer drug developer with one FDA-approved product: follicular lymphoma therapy Tazverik. The drug is a modest […]

No Image

Thought partnerships: The new frontier of client-agency partnerships

June 27, 2022 Auto Bot 0

With emerging biotech needing help with a little bit of everything, these preferred partnerships can deliver a type of one-stop shopping leveraging an agency’s best […]

No Image

How small biotech companies can make the most out of today’s deal-making landscape

June 27, 2022 Auto Bot 0

For small biotech companies that are always raising money, business development is a critical next step. Joining with a credible partner goes a long way […]

No Image

As muscular dystrophy drug meets key goal, Italfarmaco plans march forward to regulators

June 26, 2022 Auto Bot 0

A Duchenne muscular dystrophy drug candidate from Italfarmaco Group has encouraging preliminary data from a pivotal study. The Milan, Italy-based pharmaceutical company says it now […]

No Image

New data for Intellia’s CRISPR therapy shows potential for one-time treatment of a rare disease

June 24, 2022 Auto Bot 0

An Intellia Therapeutics therapy that uses CRISPR to perform in vivo genomic edits has clinical data showing that the therapeutic effects continue for a year […]

No Image

Biopharma firm Radius Health is going private in an $890M M&A deal

June 23, 2022 Auto Bot 0

Two private equity firms have reached an $890 million deal to buy Radius Health, a company whose main asset is the commercialized osteoporosis drug Tymlos. […]

No Image

Novartis picks Precision Bio to bring in vivo gene editing meds to blood disorders

June 22, 2022 Auto Bot 0

Novartis is paying Precision Bio $75 million up front to begin a partnership aiming to develop in vivo gene-editing therapies for serious genetic blood disorders, […]

No Image

AbbVie’s blockbuster drug Skyrizi gets FDA nod for treating Crohn’s disease

June 20, 2022 Auto Bot 0

AbbVie drug Skyrizi is now approved for Crohn’s disease, making it the first treatment for the disorder that addresses a particular protein associated with inflammation. […]

No Image

Report: Whistleblower accuses CVS of “calculated and widespread” drug pricing scheme targeting elderly patients

June 17, 2022 Auto Bot 0

CVS Health intentionally prevented certain Medicare beneficiaries from accessing less expensive, generic prescriptions, according to […]

No Image

Pfizer, Moderna Covid-19 vaccines are now authorized for kids as young as 6 months

June 17, 2022 Auto Bot 0

Covid-19 vaccines from Pfizer and Moderna now have FDA emergency use authorization for children as young as 6 months old. If the Centers for Disease […]

No Image

Excited about investing in a promising early-stage healthcare company?

June 16, 2022 Auto Bot 0

As a VC, if you start thinking about commercialization until after you’ve made the investment, then you’ll need a lot more than just good luck […]

No Image

November will bring political change. Will it also change drug prices and PDUFA?

June 16, 2022 Auto Bot 0

Drug prices are on the minds of patients and politicians. The November election is expected to tip the balance of power in Congress and a […]

No Image

New study: The next pandemic is coming in hot. Here’s how we speed up life-saving research

June 15, 2022 Auto Bot 0

Rapid and effective research is the only way to stave off massive loss of human life over the next 50 years. Fortunately, there are three […]

No Image

Tessa Therapeutics takes in $126M for cell therapies, and more biotech financings

June 12, 2022 Auto Bot 0

Ten biotech companies were able to raise more than $500 million in combined financing in the past week. Here’s a recap of the funding activity, […]

No Image

A call to action for pharma manufacturers: Rise to the challenge of global medicine access with the help of digitalization

June 10, 2022 Auto Bot 0

Operational efficiency and visibility brought on by digital transformation can help improve how pharmaceutical manufacturers do their critical part in improving equitable access and availability […]

No Image

Report: Deals continue downward slide for biopharma tech

June 10, 2022 Auto Bot 0

During first three months of 2022, biopharma tech companies raised less money and made fewer dealsthan they did in the last three months of 2021. […]

No Image

GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers

June 9, 2022 Auto Bot 0

A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six […]

No Image

Roche bispecific drug Lunsumio lands European nod in follicular lymphoma

June 9, 2022 Auto Bot 0

Follicular lymphoma patients in Europe now have a new treatment option. The European Commission approved Roche drug Lunsomio, a bispecific antibody designed to go after […]

No Image

ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more

June 8, 2022 Auto Bot 0

Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some […]

No Image

Biotech startup with AlphaGo-type AI approach snags $30M

June 8, 2022 Auto Bot 0

The CEO of Anagenex believes that the company’s AI engine trained on billions of data points and iterative testing will blow other AI drug discovery […]

No Image

Code Bio corrals $75M to skip viruses, use synthetic DNA for genetic meds delivery

June 7, 2022 Auto Bot 0

Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered […]

No Image

Key metrics for successful D&I in the drug development lifecycle

June 6, 2022 Auto Bot 0

Taking steps to eliminate health disparities among people of color and ensuring diversity throughout the development cycle should be a strategic goal for all. Medical […]

No Image

Becton Dickinson buys into pharmacy automation with $1.5B Parata acquisition

June 6, 2022 Auto Bot 0

Becton Dickinson is getting into pharmacies with a more than $1.5 billion acquisition of Parata Systems, maker of robotics technologies that automate pharmacy tasks. The […]

No Image

Drug-industry survey blames insurer practices for barriers to care

June 6, 2022 Auto Bot 0

Pharma companies often take the blame for high prescription costs. But a new, industry-sponsored survey shifts attention to insurance industry practices.

No Image

Repare relinquishes cancer drug to Roche, gets $125M to finance growing pipeline

June 2, 2022 Auto Bot 0

Roche’s deep oncology pipeline is adding a drug candidate from Repare Therapeutics that works by interfering with a DNA repair mechanism of cancer cells. Repare […]

No Image

Digital endpoints: Global opportunities and clinical, data protection and other challenges

May 27, 2022 Auto Bot 0

In December, the FDA published a draft guidance providing its recommendations on the use of digital health data acquisition in clinical investigations, signaling that regulatory […]

No Image

Covid-19 roundup: Boosters for kids, CAR-NK cell therapy, Paxlovid rebound & more

May 27, 2022 Auto Bot 0

Pfizer and BioNTech reported positive clinical data for a Covid-19 booster in children younger than 5, results released ahead of a June FDA advisory committee […]

No Image

It’s time to integrate liquid biopsy into colorectal cancer treatment decision-making

May 26, 2022 Auto Bot 0

Since it measures the total amount of circulating DNA (ctDNA) in a patient’s bloodstream using a simple blood draw, ctDNA liquid biopsy tests offers oncologists […]

No Image

What has Covid-19 taught us about virtual clinical trials?

May 24, 2022 Auto Bot 0

At the upcoming INVEST PharmaTech virtual conference scheduled for July 26, the conversations will span myriad topics at the intersection of digital health and drug […]

No Image

Innoviva’s Entasis acquisition brings a novel antibiotic that’s ready for the FDA

May 23, 2022 Auto Bot 0

Entasis Therapeutics is being acquired by Innoviva in a deal that brings an FDA-ready antibiotic developed to address drug-resistant strains of a bacterium that infects […]

No Image

CAR T without the toxicity: Kelonia gets $50M for a new take on cell therapy

May 22, 2022 Auto Bot 0

Kelonia Therapeutics is developing cell therapies made by the in vivo engineering of a patient’s cells made possible by the targeted delivery of a genetic […]

No Image

FDA sounds caution on Foghorn cancer drug with a partial hold after patient death

May 19, 2022 Auto Bot 0

The lead cancer drug candidate of Foghorn Therapeutics is now under a partial clinical hold following a patient death. According to the biotech, the patient […]

No Image

House Energy and Commerce Committee passes bill outlining FDA procedures to withdraw a drug

May 19, 2022 Auto Bot 0

To withdraw a drug from the market, the FDA will have to provide the drug sponsor with notice and an explanation as well as the […]

No Image

Enanta RSV drug fails a Phase 2 test, but studies continue in higher-risk patients

May 19, 2022 Auto Bot 0

An antiviral that Enanta Pharmaceuticals is developing for respiratory syncytial virus infection failed to beat a placebo in its first Phase 2 test. But the […]

No Image

INVEST Pitch Perfect winner: Modality.ai makes Tina the Alexa of clinical trials

May 18, 2022 Auto Bot 0

Modality.ai has developed a conversational AI system that replaces in-person interviews that are part of neurological assessments for a range of disorders. The startup was […]

No Image

Clover Therapeutics turns a new leaf as Character Bio to pursue dry AMD & more

May 17, 2022 Auto Bot 0

Dry age-related macular degeneration currently has no FDA-approved treatments but the research of Clover Therapeutics has yielded two candidates. The biotech startup has made progress […]

No Image

To focus on cancer, Chimerix sells rights to antiviral drug that defined the biotech

May 16, 2022 Auto Bot 0

Chimerix is selling global rights to smallpox drug Tembexa, the biotech’s only FDA-approved product, as a way to fund clinical development of a therapy in […]

No Image

Claiming Akebia agreement breach, Otsuka seeks to end anemia drug pact

May 16, 2022 Auto Bot 0

Otsuka Pharmaceutical is ending its alliance with Akebia Therapeutics, a move that comes less than two months after the FDA rejected their partnered anemia drug, […]

No Image

BMS builds on BridgeBio alliance, inking deal for rights to KRAS cancer drug

May 12, 2022 Auto Bot 0

Bristol Myer Squibb is getting rights to BBP-398, a contender in the chase for drugs that address difficult-to-target KRAS mutations. Meanwhile, BridgeBio Pharma receives some […]

No Image

Startup Nuvig Therapeutics gets $47M to bring immune system back into balance

May 11, 2022 Auto Bot 0

Nuvig Therapeutics is developing drugs that tap into one of the body’s natural mechanisms for controlling inflammation. Co-founder and CEO Pamela Conley, a veteran of […]

No Image

Regulatory recap: J&J vaccine limits, full Enhertu approval, a Vertex hold & more

May 8, 2022 Auto Bot 0

The FDA amended emergency authorization of Johnson & Johnson’s Covid-19 vaccine. In other regulatory news this past week, drug approvals include a cancer drug that […]

No Image

Novel drug-discovery approach lands big backers

May 6, 2022 Auto Bot 0

UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare diseases.

No Image

Biogen gets in tune with MedRhythms to develop new digital therapeutic for MS

May 5, 2022 Auto Bot 0

Biogen struck a deal that could bring a digital therapeutic to its multiple sclerosis product portfolio. The drugmaker is partnering with startup MedRhythms in the […]

No Image

Study finds health system specialty pharmacies linked to reduced cost of care for MA patients

May 3, 2022 Auto Bot 0

A study published in the Journal of Managed Care + Specialty Pharmacy found Medicare Advantage patients reduced their cost of care by using specialty pharmacies […]

No Image

California opens Medicaid to older unauthorized immigrants

May 2, 2022 Auto Bot 0

Unauthorized immigrants over age 49 who fall below certain income thresholds are now eligible for full coverage by Medi-Cal, California’s version of Medicaid. If Gov. […]

No Image

FDA lifts Pfizer gene therapy clinical hold, but trial adds new safety measures

April 28, 2022 Auto Bot 0

Pfizer now has the regulatory O.K. to resume pivotal tests of its gene therapy for Duchenne muscular dystrophy—but with new limitations and safety measures. The […]

No Image

Biohaven migraine drug partnered with Pfizer lands twin European approvals

April 27, 2022 Auto Bot 0

The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for Biohaven, it’s also a win for Pfizer, which […]

No Image

Community welcomes President Biden’s call to action to rein in high drug prices

April 24, 2022 Auto Bot 0

Now is the time for Congress to answer President Biden’s call to action and pass meaningful drug pricing reform that addresses the artificially inflated cost […]

No Image

AstraZeneca’s long-acting Covid-19 drug keeps protecting high-risk patients at 6 months

April 21, 2022 Auto Bot 0

AstraZeneca’s Covid-19 antibody drug Evusheld reduced the risk of infection by 83% after six months. These results published in the New England Journal of Medicine […]

No Image

BMS joins Octant’s $80M financing and signs on as a drug discovery partner

April 21, 2022 Auto Bot 0

Octant Bio’s synthetic biology approach to drug discovery is making progress, and the preclinical biotech has raised $80 million in Series B financing to continue […]

No Image

Regeneron captures new piece for cancer with $250M Checkmate Pharma buyout

April 19, 2022 Auto Bot 0

Regeneron Pharmaceuticals is paying $250 million cash to acquire Checkmate Pharmaceuticals, a clinical-stage biotech developing drugs that activate the innate immune system. The biotech’s lead […]

No Image

Covid news roundup: Boosters for kids, breath diagnostic, a vax approval & more

April 17, 2022 Auto Bot 0

Pfizer and BioNTech reported preliminary clinical data supporting use of their Covid-19 vaccine as a booster in children ages 5 to 11. In other Covid […]

No Image

BMS and Nektar end cancer drug alliance after two more clinical trial failures

April 14, 2022 Auto Bot 0

Bristol Myers Squibb and Nektar Therapeutics are ending a cancer drug research alliance after data showed the combination of their respective drugs failed clinical trials […]

No Image

Cell therapy developer Be Bio hauls in $130M for pipeline in rare disease, cancer

April 14, 2022 Auto Bot 0

Be Biopharma is developing cell therapies by engineering B cells to churn out therapeutic proteins with an initial focus on cancer and rare disease. The […]

No Image

CEO of upstart PBM: What CVS, Cigna and other PBMs are doing in drug pricing is neither sustainable nor ethical

April 12, 2022 Auto Bot 0

A.J. Loiacono was speaking at MedCity INVEST in late March in Chicago when an audience member requested him to address whether it is sustainable to […]

No Image

FDA gives Gilead reprieve on partial hold for cancer drug studies

April 12, 2022 Auto Bot 0

An FDA safety review has cleared Gilead Sciences to resume five clinical trials that were placed under a partial hold in January. The experimental Gilead […]

No Image

Aiming to make better mRNA vaccines, BioNTech strikes up alliance with Matinas

April 11, 2022 Auto Bot 0

Oral delivery of messenger RNA is one of the capabilities of Matinas BioPharma’s technology. BioNTech will explore that feature among others under a new research […]

No Image

CA handed its Medicaid drug program to a company. Then came a corporate takeover.

April 11, 2022 Auto Bot 0

California awarded the Medi-Cal Rx program to a unit of Magellan Health, a company with expertise in pharmacy benefits and mental health. But Magellan was […]

No Image

Werewolf cancer drug strikes right note with Jazz Pharma, sparking licensing deal

April 7, 2022 Auto Bot 0

Jazz Pharmaceuticals is licensing rights to a Werewolf Therapeutics cytokine therapy that’s on track to reach clinical testing next year. The deal gives Jazz a […]

No Image

Pfizer broadens its RSV reach with deal for ReViral and its clinical-stage antivirals

April 7, 2022 Auto Bot 0

Pfizer is already in the mix of companies pursuing vaccines for respiratory syncytial virus. The pharma giant is now broadening its scope with a deal […]

No Image

Imara’s two trial flops in blood disorders dim drug’s prospects in heart failure

April 5, 2022 Auto Bot 0

The lead drug candidate of Imara failed two separate mid-stage clinical trials evaluating it in rare, inherited hemoglobin disorders. Imara had been planning to advance […]

No Image

FDA places partial hold on Curis cancer drug after patient death in clinical trial

April 4, 2022 Auto Bot 0

The FDA placed a partial hold on a Curis drug in development for treating leukemia after a patient treated in a clinical trial died. The […]

No Image

The diagnostic dilemma of co-infections requires novel solutions

April 4, 2022 Auto Bot 0

Metagenomics offers advances for infectious disease diagnostics by providing the diagnostic technology to detect a potentially unlimited numbers of known and novel microbes from a […]

No Image

Becton Dickinson spins off diabetes biz, enabling Embecta to embark on its own

April 1, 2022 Auto Bot 0

The second quarter of 2022 kicked off with a new life sciences company joining the public markets, but not via an IPO or merger. Becton […]

No Image

Safety concerns sink Akebia drug for anemia from chronic kidney disease

April 1, 2022 Auto Bot 0

The FDA rejected Akebia Therapeutics drug vadadustat as a treatment for anemia caused by chronic kidney disease. According to the biotech, the agency cited safety […]

No Image

Thread, AWS partner on next-gen tech for clinical trials

March 31, 2022 Auto Bot 0

The partners aim to make decentralized clinical trials more efficient and less expensive through greater use of AI and machine learning.

No Image

At a Tennessee crossroads, two pharmacies, a monkey, and millions of pills

March 30, 2022 Auto Bot 0

Federal prosecutors have unveiled a rare criminal case alleging that owners of a pharmacy in Celina, Tennessee intentionally courted opioid seekers by filling dangerous prescriptions […]

No Image

As cash keeps pouring into health startups, VC firms work to stay disciplined

March 30, 2022 Auto Bot 0

Venture capital investment in healthcare startups is continuing at a steady pace. Is it too much? Is a correction coming? Three investors offered their perspectives […]

No Image

Data and regulatory roundup: Pfizer’s feat, an ADHD miss, Eli Lilly’s CRL & more

March 27, 2022 Auto Bot 0

A pharmaceutical giant reported a Phase 3 success for a potential blockbuster drug, while four other companies reported disappointing data from their respective clinical trials. […]

No Image

AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test

March 25, 2022 Auto Bot 0

AN2 is developing an antibiotic based on boron chemistry that could offer advantages over carbon-based molecules. The biotech plans to advance its drug candidate, licensed […]

No Image

Covid antivirals: How the last mile can save those at highest-risk

March 25, 2022 Auto Bot 0

Fixing the last mile may not be as sexy as sprinting toward the development of the mRNA vaccines or our first anti-viral treatments, but addressing […]

No Image

Hearing is believing in clinical trials

March 25, 2022 Auto Bot 0

The direct recording and analysis of voice ensures that a more diverse range of patients is represented in clinical trials. This is crucial for effective therapeutic […]

No Image

Ligand Pharma turns to a SPAC to take antibody biz public, raise up to $266M

March 24, 2022 Auto Bot 0

OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 […]

No Image

Celsius Therapeutics heats up with $83M and an IBD drug on path to the clinic

March 24, 2022 Auto Bot 0

Single-cell analysis biotech Celsius Therapeutics has raised $83 million to advance its pipeline of drugs for autoimmune disorders and cancer. The startup’s lead autoimmune program, […]

No Image

Pfizer CEO pushes annual Covid shot, but experts disagree

March 22, 2022 Auto Bot 0

When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second […]

No Image

Study: Machine learning successfully tracks drugs stolen from hospitals faster and with minimal error

March 22, 2022 Auto Bot 0

A retrospective study published in American Journal of Health-System Pharmacy found that machine learning and advanced analytics technology not only identifies drug diversion – when […]

No Image

Connecting the healthcare data dots: How a harmonized healthcare data strategy can create efficiencies

March 21, 2022 Auto Bot 0

When the healthcare industry talks about data, the conversation usually focuses on interoperability and data standards. While these are certainly important, the most effective way […]

No Image

Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy

March 21, 2022 Auto Bot 0

AnHeart Therapeutics is developing a pipeline of precision oncology therapeutics. Chief Business Officer and Co-founder Lihua Zheng provided an overview of company’s strategy in response […]

No Image

Zosano Pharma cuts staff 31%, the latest layoffs in a wave of biotech belt-tightening

March 18, 2022 Auto Bot 0

Regulatory setbacks for a new migraine treatment have led Zosano Pharma to restructure, laying off about 31% of its staff. Zosano is one of several […]

No Image

Restoring trust in clinical trials among Black communities

March 18, 2022 Auto Bot 0

Whether seeking to overcome ongoing hesitation of the Covid-19 vaccine or searching for moonshot cancer solutions, whatever the healthcare need demands, seeking results for diverse […]

No Image

Illumina Accelerator unveils 7 genomics startups selected for latest funding cycle

March 17, 2022 Auto Bot 0

Illumina Accelerator has invested in 68 companies so far, all of them startups developing genomics technologies. Seven startups comprise the latest cohort selected by the […]

No Image

Biotech startup Eclipse Bio emerges to shed light on RNA drug research

March 16, 2022 Auto Bot 0

Scientists developing new RNA drugs need to understand how proteins bind to these molecules. Eclipsebio’s technology provides that analysis and the biotech startup now has […]

No Image

RNA biotech Nutcracker Therapeutics unshells $167M for drugs built on biochips

March 14, 2022 Auto Bot 0

ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and […]

No Image

Modest activity, tolerability issues sink lead Harpoon cancer drug prospect

March 11, 2022 Auto Bot 0

Harpoon Therapeutics is discontinuing work on its lead drug in prostate cancer following disappointing data in an early-stage clinical trial. Though Harpoon has other drugs […]

No Image

Novartis turns to Voyager Therapeutics to get gene therapies into the brain

March 8, 2022 Auto Bot 0

Novartis is paying Voyager Therapeutics $53 million up front to begin a partnership focused on the discovery of capsids for central nervous system disorder gene […]

No Image

Bloomberg: Court docs reveal J&J’s role in prison tests comparing talc to asbestos

March 7, 2022 Auto Bot 0

Research of Johnson & Johnson’s baby powder included a prison study in which inmates, mostly Black men, were injected with asbestos. The study was intended […]

No Image

FDA regulatory roundup: two approvals, three rejections & one clinical hold

March 6, 2022 Auto Bot 0

The FDA approved drugs from Johnson & Johnson and CTI BioPharma in the past week. Complete response letters were issued to Gilead Sciences, Amryt, and […]

No Image

Princeton spinout ArrePath gets $20M to combine AI, imaging in antibiotics R&D

March 4, 2022 Auto Bot 0

Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to […]

No Image

Eli Lilly to stand trial over Medicaid rebate payments

March 4, 2022 Auto Bot 0

A judge ruled the lawsuit against Eli Lilly for their Medicaid rebate payments will proceed to trial; Ely Lilly is accused of underpaying for Medicaid […]

No Image

Nonprofit drugmaker Civica Rx unveils plans for insulin biosimilars, $30 per vial

March 3, 2022 Auto Bot 0

Civica Rx plans to make lower cost versions of three branded insulin products, biosimilars that are expected to reach the market in 2024. In addition […]

No Image

AbbVie makes neuro drug connection with $130M Syndesi Therapeutics acquisition

March 2, 2022 Auto Bot 0

AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential applications in a range of cognitive disorders. Syndesi is based […]

No Image

Sanofi and DarioHealth team up on digital health tools for chronic conditions

March 1, 2022 Auto Bot 0

Sanofi and digital therapeutics company DarioHealth will work together to promote the tech firm’s offerings for the management of chronic diseases. Under the $30 million, […]

No Image

Which pharmatech startups will present at MedCity INVEST’s Pitch Perfect contest?

March 1, 2022 Auto Bot 0

Five companies will present to a group of investor judges. They will be evaluated on criteria such as business idea, market opportunity, and revenue model.

No Image

A clarion call to improve mental health treatment post-Covid-19

March 1, 2022 Auto Bot 0

Leveraging a precision prescribing platform with embedded genomic analysis will help physicians improve care and reduce costs by providing valuable information to inform mental health […]

No Image

Biocon expands portfolio & market reach with $3.3B buyout of Viatris biosimilars

February 28, 2022 Auto Bot 0

Biocon Biologics is acquiring the biosimilars business of its longtime partner, Viatris. The deal gives Biocon a biosimilars presence in both emerging and developed markets, […]

No Image

Healthcare firms were pushed to confront racism. Now some are investing in Black startups.

February 25, 2022 Auto Bot 0

The racial reckoning of the past couple of years has inspired many industries to take a look at their histories and practices.

No Image

Why the FTC’s recent decision to not study PBMs might hurt consumers and independent pharmacies

February 25, 2022 Auto Bot 0

With its ruling to maintain the status quo, the FTC has decided to take a back-seat and force independent pharmacies to fend for themselves in […]

No Image

Kodiak Sciences’ trial failure clouds eye drug’s prospects for challenging Eylea

February 24, 2022 Auto Bot 0

A Kodiak Sciences drug failed to beat a Regeneron Pharmaceuticals product in a key test in the wet form of age-related macular degeneration. The biotech […]

No Image

Cash woes at neuro biotech Yumanity lead to 60% staff cut and search for a buyer

February 17, 2022 Auto Bot 0

Yumanity’s corporate restructuring means the biotech is now exploring “strategic alternatives” that could include a sale of the company or its assets. The biotech’s lead […]

No Image

J&J partners with startup Remix, aiming to treat disease by “tuning” RNA

February 17, 2022 Auto Bot 0

Several biotech companies are rising to the challenge of developing small molecules to drug RNA. Remix Therapeutics is joining the chase, but its different approach […]

No Image

Solution to big gene therapy obstacle leads to Spain’s largest biotech Series A round

February 16, 2022 Auto Bot 0

SpliceBio will use its €50 million in financing to advance development of a gene therapy for Stargardt disease, a rare eye disorder. The biotech’s technology […]

No Image

Alexa joins the site staff: how clinical trials tech will evolve in 2022

February 15, 2022 Auto Bot 0

Expect more clinical trial sponsors to embrace these technologies as the industry sees wider adoption of decentralized clinical trials.

No Image

AI-biotech Terray emerges with $60M and a solution for data problems in drug R&D

February 15, 2022 Auto Bot 0

Terray Therapeutics uses tiny microarrays to test molecules against targets of interest, then applies artificial intelligence to build large chemical datasets. The startup’s Series A […]

No Image

IQVIA report: Drug R&D reaches new highs, and not just for Covid-19 products

February 13, 2022 Auto Bot 0

The biopharmaceutical industry continues to be a hotbed of activity, with more than 6,000 products in active development and a growing share of that innovation […]

No Image

Outlook dims for ProQR’s RNA therapy for vision loss following failure in key test

February 11, 2022 Auto Bot 0

The lead RNA therapy from ProQR Therapeutics has failed the main and secondary goals of a pivotal study testing it as a treatment for a […]

No Image

Now is the time to tackle medication adherence in clinical trials

February 11, 2022 Auto Bot 0

Integrating advanced technologies, including smart packaging and powerful data analytics, is driving a revolution in adherence monitoring that is accelerating drug development timelines, lowering clinical […]

No Image

Neuro-focused Arkuda raises $64M as dementia drug moves closer to the clinic

February 10, 2022 Auto Bot 0

Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited […]

No Image

Behind the scenes: The role data plays in getting new therapeutics to market

February 8, 2022 Auto Bot 0

In a competitive market, data that help companies find these critical resources can accelerate clinical trials and shorten time to market – sometimes by years.

No Image

AI-driven Congruence Therapeutics gets $50M to stabilize misfolded proteins

February 8, 2022 Auto Bot 0

Biotech startup Congruence Therapeutics is developing novel drugs that treat disease by stabilizing misfolded proteins. Key to the company’s approach is a computational platform that […]

No Image

Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis

February 8, 2022 Auto Bot 0

Endeavor BioMedicines aims to kill two birds with one stone—that stone being a small molecule drug. Taladegib targets a cell signaling pathway associated with both […]

No Image

Unity Bio slashes headcount in half to save cash ahead of eye drug readouts

February 4, 2022 Auto Bot 0

Unity Biotechnology’s corporate restructuring is a cash-saving move that allows the company to focus resources on its lead program, a drug in Phase 2 testing […]

No Image

Softbank leads Dewpoint’s $150M round as multiple programs march toward clinic

February 3, 2022 Auto Bot 0

Dewpoint is developing drugs targeting biomolecular condensates, tiny droplets in cells that contain proteins and nucleic acids. Dysfunction of these organelles can play a role […]

No Image

Blue Cross settles class action suit naming ‘pharma bro’ Martin Shkreli for $28M

February 2, 2022 Auto Bot 0

Shkreli controversially raised the price of the drug Daraprim, which is used to treat a potentially fatal parasitic infection, by 4,000%, from $13.50 to $750 […]

No Image

Digital collaboration here to stay beyond pandemic for Merck, Pfizer, others

February 1, 2022 Auto Bot 0

A recent survey pulled medical affairs thought leaders and found that a majority see asynchronous virtual options in conjunction with in-person as the preferred path […]

No Image

Pfizer bows out of developing cardio drug, returns rights to Ionis Pharmaceuticals

February 1, 2022 Auto Bot 0

Sometimes even a clinical trial where the endpoints have been met may not give the […]

No Image

Clinical trials startup comes out of stealth by announcing $27.5M funding round

January 30, 2022 Auto Bot 0

Topography Health announced their 27.5M series A funding for their clinical trials technology led by Andreessen Horowitz and Bain Capital Ventures.

No Image

Three pharmacy trends that will define 2022

January 28, 2022 Auto Bot 0

The pharmaceutical industry made more headlines in 2021 than in any other year in recent memory. And 2022 is set to be a monumental year […]

No Image

Foresite and GV pour $40M into startup’s move to CHIP into new disease biology

January 27, 2022 Auto Bot 0

TenSixteen Bio has emerged from stealth aiming to develop drugs for diseases caused by genetic mutations accumulated as we age. The startup has been incubating […]

No Image

3 forecasts for the PBM industry in 2022

January 27, 2022 Auto Bot 0

The current landscape heading into 2022 will keep pharmacy benefits under the microscope. Plan sponsors will evaluate their PBM’s pricing model to determine if their […]

No Image

Palliative care: An essential resource in caring for those with advanced illness

January 27, 2022 Auto Bot 0

Palliative care must be the standard of care for all who have been diagnosed with progressive, advanced, and terminal illnesses. Never should we hear the […]

No Image

MedCity Pivot Podcast: A conversation with Stoke Therapeutics CMS regarding how to tackle Dravet Syndrome

January 26, 2022 Auto Bot 0

Barry Ticho explains the novel drug that the company is developing to tackle Dravet Syndrome as well as how the company’s stock price decline isn’t […]

No Image

What is inflation’s impact on clinical trials?

January 25, 2022 Auto Bot 0

Basic organic chemicals used for the preparation of new medications cost over 54.8% more than they did 12 months ago. Further, with schools and daycare […]

No Image

A new approach to managing surgical site infections: using multi-layer formulations in extended-release antibiotics

January 25, 2022 Auto Bot 0

Physicians may soon have a solution that could be ideal for preventing surgical site infections with a combined multi-layered system that provides the surgical site […]

No Image

AI firm BenchSci raises $50M for tech that takes waste out of preclinical research

January 24, 2022 Auto Bot 0

BenchSci’s technology uses artificial intelligence to make drug R&D faster and more efficient. Big pharmaceutical companies and clinical-stage biotechs are current users of the software, […]

No Image

Pfizer’s growth hormone deficiency drug comes up short at the FDA

January 23, 2022 Auto Bot 0

The FDA has rejected Pfizer’s somatrogon, a long-acting form of human growth hormone designed for once-weekly dosing. The setback delays Pfizer and partner Opko Health […]

No Image

Kura Oncology leukemia clinical trial to resume after FDA lifts partial hold

January 21, 2022 Auto Bot 0

The FDA placed the partial hold on the study last November following a patient death suspected to be linked to a known complication of leukemia […]

No Image

Psychedelic biotech Eleusis enters SPAC deal to take depression drug to the clinic

January 21, 2022 Auto Bot 0

Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target […]

No Image

ImmPACT Bio reels in $111M to prevent tumor escape with novel cell therapies

January 20, 2022 Auto Bot 0

Despite the targeted approach of some cancer treatments, tumors can find ways to escape, leading patients to relapse. ImmPACT Bio will apply its Series B […]

No Image

J&J’s investment arm joins $150M investment in digital health firm Verana

January 17, 2022 Auto Bot 0

Digital health company Verana Health has raised $150 million. The company said it will use the new capital to expand its technology, which is used […]

No Image

AstraZeneca bets $75M on Scorpion’s precision approach to tough cancer targets

January 13, 2022 Auto Bot 0

AstraZeneca’s partnership with Scorpion Therapeutics will focus on transcription factors that are known to play a role in cancer but have been difficult to target […]

No Image

BeyondSpring is laying off 35% of staff in wake of FDA rejection of lead drug

January 12, 2022 Auto Bot 0

BeyondSpring Pharmaceuticals’ corporate reorganization comes about six weeks after the FDA rejected the biotech’s drug for a complication experienced by cancer patients. The company still […]

No Image

Country’s largest pancreatic disease patient registry launches

January 12, 2022 Auto Bot 0

The National Pancreas Foundation and Seqster are partnering to create a dynamic digital database for patients with pancreatic diseases that compiles patients’ data from genomic […]

No Image

Freenome gets $290M from Roche as it preps blood-based cancer test’s next steps

January 11, 2022 Auto Bot 0

A month after Freenome closed $300 million in financing, Roche has invested another $290 million in the diagnostics developer. The cash infusion comes as Freenome […]

No Image

Pfizer, Bayer each strike up deals to add in-vivo gene editing to pipeline mix

January 10, 2022 Auto Bot 0

As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that expand give them access to in-vivo gene editing technologies. […]

No Image

Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian cancer

January 9, 2022 Auto Bot 0

The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan […]

No Image

Amylyx Pharma’s IPO lands $190M as ALS drug begins FDA review

January 7, 2022 Auto Bot 0

It’s the first week of the new year, and the life sciences sector continued the IPO momentum of 2021 as Wall Street welcomed three new […]

No Image

Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia

January 7, 2022 Auto Bot 0

Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach […]

No Image

Sanofi’s overhaul of genomic medicines strategy spells end of Sangamo alliance

January 6, 2022 Auto Bot 0

A Sanofi strategy shift is leading to the end of a gene-editing alliance with Sangamo Therapeutics. Though the partnership has produced encouraging early clinical data […]

No Image

Friendly fire: Using viruses to kill tumors and fight breast cancer

January 5, 2022 Auto Bot 0

Oncolytic viruses have the power to make the tumor more visible to the immune system and mark the area of attack. It is this anti-tumor […]

No Image

Avrobio shifts gene therapy priorities as data surprise shelves lead program

January 4, 2022 Auto Bot 0

Avrobio is stopping enrollment in a clinical trial for its Fabry disease program after new results showed variability in how the gene therapy was taken […]

No Image

Aetion acquires Replica Analytics to bring aboard synthetic data capabilities

January 4, 2022 Auto Bot 0

Health analytics firm Aetion has acquired Replica Analytics, a company that specializes in synthetic data. Aetion said Replica will enable it to analyze previously inaccessible […]

No Image

Medical education through Twitter? Pharma’s digital strategy for healthcare providers [Sponsored]

January 4, 2022 Auto Bot 0

“Most Q&As are happening on Twitter. If you’re not doing social listening you’re losing fresh insights into things like disease states.” That was just one […]

No Image

FDA expands Covid-19 boosters for kids using real-world data in much older adults

January 4, 2022 Auto Bot 0

The FDA has expanded emergency authorization of Covid-19 boosters to include children 12 to 15 vaccinated with the Pfizer and BioNTech messenger RNA shot. The […]

No Image

Ovid Therapeutics adds to epilepsy drug pipeline with new AstraZeneca alliance

January 3, 2022 Auto Bot 0

Ovid Therapeutics is acquiring global rights to AstraZeneca molecules that address a novel target to treat epilepsy. The AstraZeneca deal comes 10 months after Takeda […]

No Image

Cancer therapies lead way as FDA tallies 60 drug approvals in 2021

January 2, 2022 Auto Bot 0

As in previous years, cancer products topped the list of new FDA-approved therapies in 2021. But the list of drug approvals is notable for other […]

No Image

Cell therapy, AI drug discovery highlight 2021’s record year in biotech IPOs

December 29, 2021 Auto Bot 0

The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were […]

No Image

Newly public Pardes Bio aims to show its Covid-19 pill can offer edge over Pfizer’s

December 29, 2021 Auto Bot 0

Pardes Biosciences’ experimental oral antiviral for treating and preventing Covid-19 infection addresses the same target as Pfizer’s authorized pill Paxlovid, but with a potential dosing […]

No Image

Leo Pharma’s FDA nod adds a challenger to Dupixent’s dominance in eczema

December 28, 2021 Auto Bot 0

With FDA approval for its atopic dermatitis drug Adbry, LEO Pharma will reach the U.S market ahead of an Eli Lilly atopic dermatitis drug that […]

No Image

Heart drug’s trial failure busts bid to best Pfizer, but BridgeBio still bets on coming data

December 27, 2021 Auto Bot 0

BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients […]

No Image

FDA authorizes Merck antiviral, which joins Pfizer pill as oral option for Covid-19

December 23, 2021 Auto Bot 0

Merck antiviral drug molnupiravir received emergency authorization, joining Pfizer’s Paxlovid as the only authorized oral antiviral drugs for treating Covid-19. Though the Merck and Pfizer […]

No Image

FDA nod for Novartis sets up cholesterol drug showdown with Amgen, Regeneron

December 23, 2021 Auto Bot 0

Novartis drug Leqvio now has the FDA’s green light, making it the first RNA interference medicine approved for lowering cholesterol. The regulatory decision sets the […]

No Image

Patient death prompts FDA halt on Pfizer’s Duchenne gene therapy study

December 21, 2021 Auto Bot 0

The FDA has halted tests of a Pfizer gene therapy for Duchenne muscular dystrophy. The clinical hold is one of several placed on gene therapy […]

No Image

Sanofi’s $1B Amunix acquisition aims for targeted, safer T cell engagers for cancer

December 21, 2021 Auto Bot 0

In acquiring Amunix, Sanofi becomes the latest big pharmaceutical company to strike a deal to gain access to technology that improves the safety and efficacy […]

No Image

Novartis, BeiGene ink another deal; plan for tests of checkpoint cancer drug combos

December 20, 2021 Auto Bot 0

Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing […]

No Image

More than our stories: The do’s and don’ts of engaging patient advocates

December 20, 2021 Auto Bot 0

What follows is guidance for healthcare workers, hospital administrators, journalists, nonprofit leaders, government officials, industry leaders, and others who want to invite engage a patient […]

No Image

Biogen slashes price of Alzheimer’s drug by half as CMS coverage decision looms

December 20, 2021 Auto Bot 0

The price of Biogen Alzheimer’s disease drug Aduhelm will be cut in half at the start of 2022, a move that comes as a Medicare […]

No Image

Let’s focus on patient compliance as the problem, not adherence

December 20, 2021 Auto Bot 0

The change in terminology from “compliance” to “adherence” is based on unfounded and untenable foundations. It conflates cause and effect, and a shift in language […]

No Image

FDA approval of Argenx neuromuscular disease therapy is first in new drug class

December 19, 2021 Auto Bot 0

Myasthenia gravis patients now have a new FDA-approved biological treatment. Argenx drug Vyvgart provides a treatment alternative for patients who have the rare autoimmune disorder […]

No Image

Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 for rare liver disease

December 17, 2021 Auto Bot 0

Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but […]

No Image

4 ways AI can transform clinical trials

December 17, 2021 Auto Bot 0

We cannot simply accept that testing new drugs will continue to be a slow and expensive process. AI has the potential to disrupt the current […]

No Image

Eli Lilly joins Verge Genomics’ $98M round as AI-discovered ALS drug nears clinic

December 16, 2021 Auto Bot 0

Three life science companies unveiled Series B rounds of funding Thursday, early Christmas gifts that top $219 million combined. Along with Verge Genomics, the other […]

No Image

Biogen projects confirmatory study for Alzheimer’s drug will take four years

December 16, 2021 Auto Bot 0

Six months after Biogen was awarded regulatory approval for its Alzheimer’s disease drug Aduhelm, the company the company is laying out a timeline for the […]

No Image

Startup Mythic Therapeutics emerges with $103M to control fate of ADC cancer drugs

December 16, 2021 Auto Bot 0

Antibody drug conjugates deliver a targeted strike to tumors, but the toxic payloads of these therapies can still reach healthy tissue. Mythic Therapeutics’ FateControl technology ensures […]

No Image

CSL shakes off pandemic woes, diversifies with $11.7B Vifor Pharma acquisition

December 15, 2021 Auto Bot 0

CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. […]

No Image

BMS joins off the shelf cell therapy chase with alliance on Immatics cancer drug

December 14, 2021 Auto Bot 0

Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient’s T cells to […]

No Image

As genetic testing expands, evidence and awareness needed to spur adoption

December 9, 2021 Auto Bot 0

Genetic tests are becoming available for a wider range of applications. During a CB Insights panel discussion, Phil Febbo of Illumina and Alicia Zhou of […]

No Image

AstraZeneca’s long-acting antibody drug lands FDA authorization for Covid-19

December 9, 2021 Auto Bot 0

FDA authorization of AstraZeneca drug Evusheld makes it the first antibody therapy for preventing infection before exposure to Covid-19, providing an option for immunocompromised patients […]

No Image

First cohort of digital health startups graduates from PharmStars accelerator

December 8, 2021 Auto Bot 0

PharmStars, an accelerator for companies developing digital solutions for pharmaceutical companies, has graduated its first class of startups. The theme for this initial group was […]

No Image

Alzheimer’s disease should be approached as white matter disease, not gray

December 8, 2021 Auto Bot 0

We now know how important white matter is to our overall brain health and cognitive ability, as well as how declines in white matter structure […]

No Image

Cancer & immunology biotech Odyssey embarks with $218M, Gary Glick at helm

December 7, 2021 Auto Bot 0

Odyssey Therapeutics is the latest startup formed by serial biotech entrepreneur Gary Glick. Odyssey’s destination is oncology and immunology drugs that address novel disease targets, […]

No Image

Liberating real-world data for use in clinical trials

December 6, 2021 Auto Bot 0

Liberating the genetics, laboratory and pharmacy data that sits deep within healthcare subsystems, while protecting patient information and navigating the global regulatory landscape, is no […]

No Image

Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody design

December 6, 2021 Auto Bot 0

Nabla Bio emerged from the lab of famed Harvard scientists George Church last year, and its antibody discovery technology has already led to five partnerships […]

No Image

Early clinical data validate rare immune cell for Adicet’s off-the-shelf cancer therapy

December 6, 2021 Auto Bot 0

Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other […]

No Image

Radiation and BOTOX: Harnessing the power of nature to advance medical discovery and treatment

December 6, 2021 Auto Bot 0

What do radiation and Botox have in common? Two powerful tools that were tamed by medicine in the quest to help patients. We’ve found ways […]

No Image

Infants, kids now have a Covid-19 therapy as FDA expands use of Eli Lilly drug

December 5, 2021 Auto Bot 0

Eli Lilly’s authorized antibody drug for treating and preventing Covid-19 infection in adolescents and adults is now authorized for pediatric patients, including newborns. While tests […]

No Image

Hospitals refused to give patients ivermectin. Lockdowns and political pressure followed.

December 2, 2021 Auto Bot 0

Ivermectin and other unauthorized covid treatments have become a major source of dispute in recent months. Lawsuits over hospitals’ refusals to provide ivermectin to patients […]

No Image

With $100M ReCept M&A deal, Omnicell enters growing specialty pharmacy space

December 2, 2021 Auto Bot 0

Specialty drugs represent a growing share of overall pharmaceutical sales, and Omnicell is acquiring specialty pharmacy technologies company ReCept Pharmacy to enter into this market. […]

No Image

Novartis boosts neuro pipeline through alliance on UCB Parkinson’s drugs

December 2, 2021 Auto Bot 0

Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating […]

No Image

FDA turns down BeyondSpring chemo complication drug, asks for another trial

December 1, 2021 Auto Bot 0

BeyondSpring Pharmaceuticals said the FDA wants another clinical trial to demonstrate patient benefit for its drug, a small molecule developed to treat a dangerous and […]

No Image

Sanofi makes another mRNA move with deal for skin microbiome biotech Origimm

December 1, 2021 Auto Bot 0

Sanofi’s strategy to develop new messenger RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing […]

No Image

Children aren’t miniature adults — and deserve behavioral healthcare tailored specifically for them

November 30, 2021 Auto Bot 0

For too long, we’ve forced kids to make do with services made for adults. The results have been nothing less than tragic, as evidenced by […]

No Image

After Phase 3 failure busts blockbuster bid, Deciphera restructures; staff slashed 35%

November 30, 2021 Auto Bot 0

Deciphera Pharmaceuticals’ corporate restructuring will slash headcount by 35% and stop work on two drug programs. Going forward, the biotech said it will focus on […]

No Image

FDA study offers new tool to make sense out of pharmacogenetics data

November 30, 2021 Auto Bot 0

Prescribers need a pharmacogenetics knowledge base to determine a safe and effective medication and dosage for their patients, but they also need pharmacogenetics test information […]

No Image

Cell therapy biotech Quell adds $156M for alternative to organ transplant meds

November 29, 2021 Auto Bot 0

Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate […]

No Image

Blueprint Medicines to buy cancer drug startup with potential edge over Takeda, J&J targeted therapies

November 29, 2021 Auto Bot 0

Blueprint Medicines is paying $250 million up front to acquire Lengo Therapeutics, developer of targeted cancer therapies. The startup’s lead drug candidate is on track […]

No Image

Want the lowest-net-cost drugs? Change your thinking on disruption

November 29, 2021 Auto Bot 0

When your organization asks for a lowest-net-cost formulary, what you’re really saying is, “I want the deepest contractual discounts aligned with my formulary without disruption.”

No Image

Concern about Covid-19 variant Omicron centers on spike protein mutations

November 28, 2021 Auto Bot 0

The new Covid-19 variant, named Omicron, has mutations that could help it evade antibodies produced by the immune system. Scientists are conducting lab tests to […]

No Image

FDA hands out approvals to Takeda transplant drug, Aadi Bio cancer therapy

November 24, 2021 Auto Bot 0

Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, […]

No Image

Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front

November 22, 2021 Auto Bot 0

AbbVie returned the rights to the drugs to Sosei Heptares earlier this year. Now Neurocrine Biosciences has agreed to pay the Japanese drug company $100 […]

No Image

Vifor Pharma adds to chronic kidney disease lineup with pair of acquisitions

November 22, 2021 Auto Bot 0

Nephrology products company Vifor Pharma is shelling out about $252 million combined up front to acquire Sanifit Therapeutics and Inositec, developers of drugs for a […]

No Image

BioMarin Pharma sees big things for first FDA-approved dwarfism drug

November 21, 2021 Auto Bot 0

BioMarin Pharmaceutical’s Voxzogo is the first FDA approved therapy for achondroplasia, an inherited disorder that causes the most common form of dwarfism. With approvals in […]

No Image

Sanofi makes $270M bet that a startup’s AI tech can boost its cancer drug R&D

November 19, 2021 Auto Bot 0

The sum represents Sanofi’s equity investment in Owkin, plus a payment to begin a research partnership covering four types of cancer. Meanwhile, Owkin said the […]

No Image

Generate Bio adds $370M for big push toward programmable protein medicines

November 18, 2021 Auto Bot 0

Generate Biomedicines applies artificial intelligence and machine learning to protein analysis, which it uses to program its protein therapies for particular applications. The startup now […]

No Image

The emerging golden era of neuroscience [Sponsored]

November 18, 2021 Auto Bot 0

Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in […]

No Image

Novo Nordisk reaches $3.3B deal to acquire RNAi partner Dicerna Pharma

November 18, 2021 Auto Bot 0

The acquisition agreement comes exactly two years after the two companies began a wide-ranging alliance focused on developing RNA interference drug for metabolic disorders. The […]

No Image

RA Capital reveals next play in protein degradation, this time outside the cell

November 18, 2021 Auto Bot 0

The first wave of biotechs developing drugs that employ targeted protein degradation target disease-causing proteins inside the cell. Biotech startup Avilar Therapeutics, formed by RA […]

No Image

Aiming for on/off switch of genes, Chroma corrals $125M for new wave of medicines

November 17, 2021 Auto Bot 0

Chroma Medicine is developing epigenetic therapies that turn genes on or off. The biotech startup has emerged from stealth mode backed by a $125 million […]

Posts navigation

1 2 … 4 »

Nutrition

A Plant-Based Workplace Wellness Program Put to the Test

Auto Bot / August 18, 2022
Nutrition

What Is the Bro Diet, and Is It Healthy?

Auto Bot / August 17, 2022

Healthcare Communications Association

Get Well Launches Monkeypox Digital Care Management Plan

AutoBot / August 18, 2022
Healthcare Communications Association

Pharma giants slam Medicare drug price negotiation

AutoBot / August 18, 2022
Healthcare Communications Association

White House: Updated boosters for adults, teens expected in a few weeks

AutoBot / August 18, 2022
Healthcare Communications Association

University of Maryland reports first presumptive monkeypox case

AutoBot / August 18, 2022
Healthcare Communications Association

I ran a mental health clinic in Uvalde. Now I support a new approach

AutoBot / August 18, 2022
Healthcare Communications Association

Mental Health Parity at a Crossroads

AutoBot / August 18, 2022
Healthcare Communications Association

COVID-19 booster campaign to start on 5 September, NHS England says

AutoBot / August 18, 2022
Healthcare Communications Association

The new Teeny Tiny Stevies song ‘I got you’

AutoBot / August 18, 2022
Healthcare Communications Association

Some Rural Hospitals Are in Such Bad Shape, Local Governments Are Practically Giving Them Away

AutoBot / August 18, 2022
Healthcare Communications Association

Her Brother Landed in a Nursing Home. She Was Sued Over His Bill.

AutoBot / August 18, 2022
Healthcare Communications Association

Sleepless Nights Over Her Children’s Future as Debts Pile Up

AutoBot / August 18, 2022
Healthcare Communications Association

Beyond the Byline: Venture capital firms lure health system CEOs

AutoBot / August 18, 2022
Healthcare Communications Association

Cardiac Science – Cardiac Surgery Packages & Cost Guide

AutoBot / August 18, 2022
Healthcare Communications Association

How real-time benefit tools deliver meaningful savings

AutoBot / August 18, 2022
Healthcare Communications Association

Preventative Health Programs Need to Address 3 Key Components

AutoBot / August 18, 2022
Healthcare Communications Association

Half of Texas school districts don’t offer mental health services: report

AutoBot / August 18, 2022
Healthcare Communications Association

Health Care — Changes coming to the CDC after missteps

AutoBot / August 17, 2022
Healthcare Communications Association

Walmart, CVS and Walgreens ordered to pay $650 million to Ohio counties for opioid crisis

AutoBot / August 17, 2022
Healthcare Communications Association

With workplace violence on the rise, some health systems are hiring experts to address it

AutoBot / August 17, 2022
Healthcare Communications Association

Hearing experts applaud FDA approval of over the counter hearing aids

AutoBot / August 17, 2022

Nutrition

A Plant-Based Workplace Wellness Program Put to the Test

Auto Bot / August 18, 2022
Nutrition

What Is the Bro Diet, and Is It Healthy?

Auto Bot / August 17, 2022

Healthcare Communications Association

Get Well Launches Monkeypox Digital Care Management Plan

AutoBot / August 18, 2022
Healthcare Communications Association

Pharma giants slam Medicare drug price negotiation

AutoBot / August 18, 2022
Healthcare Communications Association

White House: Updated boosters for adults, teens expected in a few weeks

AutoBot / August 18, 2022
Healthcare Communications Association

University of Maryland reports first presumptive monkeypox case

AutoBot / August 18, 2022
Healthcare Communications Association

I ran a mental health clinic in Uvalde. Now I support a new approach

AutoBot / August 18, 2022
Healthcare Communications Association

Mental Health Parity at a Crossroads

AutoBot / August 18, 2022
Healthcare Communications Association

COVID-19 booster campaign to start on 5 September, NHS England says

AutoBot / August 18, 2022
Healthcare Communications Association

The new Teeny Tiny Stevies song ‘I got you’

AutoBot / August 18, 2022
Healthcare Communications Association

Some Rural Hospitals Are in Such Bad Shape, Local Governments Are Practically Giving Them Away

AutoBot / August 18, 2022
Healthcare Communications Association

Her Brother Landed in a Nursing Home. She Was Sued Over His Bill.

AutoBot / August 18, 2022
Healthcare Communications Association

Sleepless Nights Over Her Children’s Future as Debts Pile Up

AutoBot / August 18, 2022
Healthcare Communications Association

Beyond the Byline: Venture capital firms lure health system CEOs

AutoBot / August 18, 2022
Healthcare Communications Association

Cardiac Science – Cardiac Surgery Packages & Cost Guide

AutoBot / August 18, 2022
Healthcare Communications Association

How real-time benefit tools deliver meaningful savings

AutoBot / August 18, 2022
Healthcare Communications Association

Preventative Health Programs Need to Address 3 Key Components

AutoBot / August 18, 2022
Healthcare Communications Association

Half of Texas school districts don’t offer mental health services: report

AutoBot / August 18, 2022
Healthcare Communications Association

Health Care — Changes coming to the CDC after missteps

AutoBot / August 17, 2022
Healthcare Communications Association

Walmart, CVS and Walgreens ordered to pay $650 million to Ohio counties for opioid crisis

AutoBot / August 17, 2022
Healthcare Communications Association

With workplace violence on the rise, some health systems are hiring experts to address it

AutoBot / August 17, 2022
Healthcare Communications Association

Hearing experts applaud FDA approval of over the counter hearing aids

AutoBot / August 17, 2022

News Pharmacy

3 ways pharma can prep for Biden’s sweeping drug pricing policies

AutoBot / August 18, 2022
News Pharmacy

CSL Vifor’s Tavneos (avacopan) Receives NICE Recommendation for the Treatment of Anca-Associated Vasculitis (GPA/MPA)

AutoBot / August 18, 2022
News Pharmacy

CSL Vifor’s Tavneos (avacopan) Receives NICE Recommendation for the Treatment of Anca-Associated Vasculitis (GPA/MPA)

AutoBot / August 18, 2022
News Pharmacy

Genentech Entered into an Exclusive WW License Agreement with Jemincare to Develop and Commercialize JMKX002992 for Prostate Cancer

AutoBot / August 18, 2022
News Pharmacy

CSL Vifor’s Tavneos (avacopan) Receives NICE Recommendation for the Treatment of Anca-Associated Vasculitis (GPA/MPA)

AutoBot / August 18, 2022
News Pharmacy

Blueprint Medicines Reports (PIONEER) Trial Results of Ayvakit (avapritinib) for the Treatment of Non-Advanced Systemic Mastocytosis

AutoBot / August 18, 2022
News Pharmacy

CSL Vifor plans UK launch after NICE backs rare disease drug Tavneos

AutoBot / August 18, 2022
News Pharmacy

Mepro Pharmaceuticals Pvt. Ltd- Openings for Regulatory Affairs/ Production-Apply Now

AutoBot / August 18, 2022
News Pharmacy

New drug application accepted by FDA for GSK’s momelotinib

AutoBot / August 18, 2022
News Pharmacy

Chiesi’s Trimbow recommended for use within NHS Scotland

AutoBot / August 18, 2022
News Pharmacy

Astellas files menopause drug fezolinetant in US, setting up Feb verdict

AutoBot / August 18, 2022
News Pharmacy

Frontiers Steering Committee spotlight: Megan Coder

AutoBot / August 18, 2022
News Pharmacy

Endo files for bankruptcy as it agrees opioid settlement

AutoBot / August 18, 2022
News Pharmacy

GSK Reports the US FDA’s Acceptance of NDA for Momelotinib to Treat Myelofibrosis

AutoBot / August 18, 2022
News Pharmacy

GSK Reports the US FDA’s Acceptance of NDA for Momelotinib to Treat Myelofibrosis

AutoBot / August 18, 2022
News Pharmacy

Bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval

AutoBot / August 18, 2022
News Pharmacy

bluebird bio’s Zynteglo (betibeglogene autotemcel) Receives the US FDA’s Approval for the Treatment of Beta-Thalassemia

AutoBot / August 18, 2022
News Pharmacy

bluebird bio’s Zynteglo (betibeglogene autotemcel) Receives the US FDA’s Approval for the Treatment of Beta-Thalassemia

AutoBot / August 18, 2022
News Pharmacy

Sanofi Entered into a Multi-Target Research Collaboration with Atomwise for AI-Powered Drug Discovery

AutoBot / August 18, 2022
News Pharmacy

Aurobindo Pharma-Walk-In Interviews for Research Associate -FRD On 21st Aug’ 2022

AutoBot / August 18, 2022

Copyright © 2022 | WordPress Theme by MH Themes

en English
af Afrikaanssq Shqipam አማርኛar العربيةhy Հայերենaz Azərbaycan dilieu Euskarabe Беларуская моваbn বাংলাbs Bosanskibg Българскиca Catalàceb Cebuanony Chichewazh-CN 简体中文zh-TW 繁體中文co Corsuhr Hrvatskics Čeština‎da Dansknl Nederlandsen Englisheo Esperantoet Eestitl Filipinofi Suomifr Françaisfy Fryskgl Galegoka ქართულიde Deutschel Ελληνικάgu ગુજરાતીht Kreyol ayisyenha Harshen Hausahaw Ōlelo Hawaiʻiiw עִבְרִיתhi हिन्दीhmn Hmonghu Magyaris Íslenskaig Igboid Bahasa Indonesiaga Gaeligeit Italianoja 日本語jw Basa Jawakn ಕನ್ನಡkk Қазақ тіліkm ភាសាខ្មែរko 한국어ku كوردی‎ky Кыргызчаlo ພາສາລາວla Latinlv Latviešu valodalt Lietuvių kalbalb Lëtzebuergeschmk Македонски јазикmg Malagasyms Bahasa Melayuml മലയാളംmt Maltesemi Te Reo Māorimr मराठीmn Монголmy ဗမာစာne नेपालीno Norsk bokmålps پښتوfa فارسیpl Polskipt Portuguêspa ਪੰਜਾਬੀro Românăru Русскийsm Samoangd Gàidhligsr Српски језикst Sesothosn Shonasd سنڌيsi සිංහලsk Slovenčinasl Slovenščinaso Afsoomaalies Españolsu Basa Sundasw Kiswahilisv Svenskatg Тоҷикӣta தமிழ்te తెలుగుth ไทยtr Türkçeuk Українськаur اردوuz O‘zbekchavi Tiếng Việtcy Cymraegxh isiXhosayi יידישyo Yorùbázu Zulu